A Double Blind, Randomized, Placebo-controlled, Two-part Study to Investigate the Pharmacokinetics, Followed by Efficacy and Safety of GWP42006 as add-on Therapy in Patients With Inadequately Controlled Focal Seizures.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Cannabidivarin (Primary)
- Indications Partial epilepsies
- Focus Therapeutic Use
- Sponsors GW Pharmaceuticals
- 04 Dec 2017 According to a company media release, company expects data of the trial in Q1 2018.
- 12 May 2017 Planned End Date changed from 1 Sep 2017 to 1 Aug 2017.
- 12 May 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Jul 2017.